WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Conditions: Anaplastic Astrocytoma, IDH-Wildtype; Glioblastoma, IDH-Wildtype; Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Central Nervous System; Metastatic Malignant Neoplasm in the Leptomeninges Interventions: Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU; Procedure: Therapeutic Conventional Surgery Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Astrocytoma | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Research